LeMaitre Vascular (LMAT) stock is soaring 8.68% in pre-market trading on Wednesday, following the release of its impressive second-quarter results and an analyst upgrade. The medical device company, which specializes in products for peripheral vascular disease, has surpassed expectations and raised its full-year guidance, triggering investor enthusiasm.

The company reported Q2 earnings per share of $0.60, beating analyst expectations of $0.57. Revenue reached $64.2 million, up 15% year-over-year and surpassing estimates. The strong performance was driven by robust growth in key product categories, with catheter sales increasing by 27% and graft sales rising by 19%. LeMaitre's gross margin also expanded to 70.0%, reflecting improved manufacturing efficiencies and higher average selling prices.

Adding to the positive sentiment, Barrington Research upgraded LeMaitre Vascular from Market Perform to Outperform. This upgrade, coupled with the company's decision to raise its full-year 2025 sales and earnings guidance and increase its quarterly dividend to $0.20 per share, has further boosted investor confidence. The market's reaction suggests that investors are optimistic about LeMaitre's growth prospects and its ability to capitalize on the expanding vascular device market.